Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2026-05-25 @ 11:46 AM
Study NCT ID:
NCT04688151
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-22
First Post:
2020-12-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
Sponsor:
National Health Research Institutes, Taiwan
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Primary Central Nervous System Lymphoma (PCNSL) | View |
Keywords: